Equillium, Inc.

NASDAQ:EQ

Biotechnology

Healthcare
$1.10 +1.51%

+$0.05 today

Market cap
$90.56M
Beta
1.76
P/E (TTM)
-15.3
EPS (TTM)
-$0.20
52W Low $0.27High $3.45

Volume 0.89M

Average 0.60M

EQ Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Equillium, Inc.NASDAQ: EQ

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin not reported for Q1 FY2026

Context

  • Net margin widened in 2 of the last 2 fiscal years.
  • FY2024 was the highest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Net Margin history

Percent of revenue · from the income statement

Latest · FY2024
-19.6%
Year-over-year change
+17.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How EQ compares with its peers on the latest reported figures

EQ Competitors Peer median
Net Margin for EQ and competitors
Company Period LTM level YoY 3-year change
FBIOFortress Biotech, Inc.LTM Mar 2026193.1% +264.4 pp+125.1 pp
IPSCCentury Therapeutics, Inc.FY2025-8.8% +1912.1 pp+2509.6 pp
CUECue Biopharma, Inc.LTM Mar 2026-59.6% +448.2 pp+4161.0 pp
COEPCoeptis Therapeutics, Inc.LTM Mar 2026-839.7% +14705.1 pp—
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026-1070.3% ——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-18297.5% -30712.4 pp—
EQEquillium, Inc.FY2025— ——
SPRBSpruce Biosciences, Inc.FY2025— ——
TELOTelomir Pharmaceuticals, Inc. Common StockFY2025— ——
OSTXOS Therapies IncorporatedFY2025— ——
Peer median (excluding EQ) -449.7%+448.2 pp+2509.6 pp

Competitors are the stored peer set for EQ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue015.76M36.08M41.1M0
Cost of Revenue0000116K
Gross Profit015.76M36.08M41.1M(116K)
Gross Margin—100.0%100.0%100.0%—
Research & Development26.38M37.55M37.04M37.43M12.84M
Selling, General & Admin11.41M17.24M13.57M11.94M10.79M
Operating Expenses37.79M77.84M50.61M49.36M23.63M
Depreciation & Amortization72K118K126K137K116K
EBITDA(37.91M)(61.26M)(12.14M)(7.57M)(22.28M)
EBITDA Margin—-388.7%-33.6%-18.4%—
Operating Income(37.79M)(62.08M)(14.52M)(8.27M)(23.63M)
Operating Margin—-393.9%-40.2%-20.1%—
Interest Income57K420K2.33M1.38M833K
Interest Expense1.07M1.05M491K00
Other Income / Expenses(1.27M)(352K)1.77M563K1.24M
Income Before Tax(39.05M)(62.43M)(12.76M)(7.71M)(22.4M)
Pre-Tax Margin—-396.1%-35.3%-18.8%—
Income Tax Expense00580K361K0
Net Income(38.98M)(62.43M)(13.34M)(8.07M)(22.4M)
Net Margin—-396.1%-37.0%-19.6%—
EPS (Basic)(1.35)(3.19)(0.38)(0.23)(0.39)
EPS (Diluted)(1.35)(3.19)(0.38)(0.23)(0.39)
Weighted Avg Shares28.81M33.73M34.73M35.36M91.88M
Weighted Avg Shares (Diluted)28.81M33.73M34.73M35.36M91.88M

Equillium, Inc.

NASDAQ:EQ

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.